Exchange: OTC·Updated 08:05 AM EDT

DYMDF Diamyd Medical AB - Ordinary Shares - Class B

$0.73
$0.5942
(81.40%)
Pre-Market
Prev Close $0.73
Mkt Cap$113.14M
Vol43.00

About DYMDF

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen, which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. The company also develops and invests in stem cell and medical technology. Diamyd Medical was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.
50

Neutral Sentiment

How do you feel about DYMDF?

Advertisement|Remove ads.